1. Introduction {#sec1}
===============

Bladder cancer (BC) is a common urogenital cancer, with an estimate of 80,470 new cases and 17,670 deaths in the United States in 2019 \[[@B1]\]. Bladder cancer patients are often diagnosed by cystoscopy for diagnostic testing prompted by haematuria. Approximately 80% of urinary bladder tumors are superficial papillary lesions but also can be multifocal and exhibit a tendency for recurrence: remaining tumors may invade the bladder wall and lead to distant metastases \[[@B2]\]. Treatment for BC includes transurethral resection of bladder tumor (TURBT), chemotherapy, or vaccine-based therapy directed to the bladder, cystectomy, radiotherapy, and chemotherapy \[[@B3]\]. However, BC is a complex disease associated with a high recurrence rate and high mortality, and its biology remains poorly understood \[[@B4]\].

There are several important risk factors for BC, such as cigarette smoking, occupational chemical exposure (especially to aromatic amines), water arsenic level, *Schistosoma haematobium* infection, and radiation therapy for pelvic malignancies \[[@B5]\]. Previous studies identified aspects of the molecular mechanism of BC development and recurrence. BC has been genetically associated with mutations of two genes, fibroblast growth factor receptor 3 (FGFR3, for low-grade, noninvasive papillary tumors), and tumor protein P53 (TP53, for high-grade, muscle-invasive tumors) \[[@B6]\]. Treatment with drugs targeting mutations in genes such as FGFR3, VEGF, signal transducer and activator of transcription 3, and CD24 has all shown preclinical activity \[[@B4]\]. Next-generation sequencing (NGS) has drastically increased the understanding of cancer processes including BC, and analyses of these data can provide insight into effective diagnostic and therapeutic BC treatments \[[@B7], [@B8]\].

There are significant BC molecular profiling data \[[@B9]--[@B12]\]. Researchers have explored screening of urine to detect DNA mutations as an alternative for urine cytology as a tool for the noninvasive detection and surveillance of BC \[[@B13]\]. Additionally, the analysis of frequently mutated genes in BC may suggest potential targets for personalized treatment and predict treatment response \[[@B8]\]. However, to date, it has been difficult to identify key genes related to BC from NGS data. To discover key molecules active in BC, we analyzed BC data from microarray experiments and NGS sequencing data of clinical specimens. Our results suggested CCNB1, ESPL1, CENPM, BLM, and ASPM may contribute to BC development and recurrence.

2. Materials and Methods {#sec2}
========================

2.1. Online Data {#sec2.1}
----------------

The gene expression profiling datasets of bladder cancer were analyzed online (GEO; <https://www.ncbi.nlm.nih.gov/geo/geo2r/?acc=GSE13507>). 58 normal tissues surrounding cancer, 165 primary bladder cancer, and 23 recurrent samples were measured in this array.

2.2. Identifying Differentially Expressed Genes {#sec2.2}
-----------------------------------------------

To analyze the microarray data, we compared the gene expression between 58 normal tissues surrounding cancer and 165 primary bladder cancer samples to identify genes involved with tumorigenesis, and gene expression comparison between 165 primary bladder cancer and 23 recurrent samples was also performed to screen genes that promote tumor recurrence. Differentially expressed genes were screened by adjusted *p* value or *p* value and fold change (FC). For comparison between surrounding tissue and cancer tissue, differentially expressed genes were restricted by adjusted *p* value \<0.05 and \|FC\| \> 4, and we defined these genes cluster SC (surrounding tissue vs. cancer tissue). For comparison between cancer tissue and recurrent tissue, differentially expressed genes were restricted by *p* value \<0.05 and \|FC\| \> 2, and we defined these genes cluster CR (cancer tissue vs. recurrent tissue).

2.3. Merging Data {#sec2.3}
-----------------

We proposed two methods to process the clusters SC and CR: (1) tumorigenesis and recurrence were promoted by the same genes or proteins, the overlap between SC and CR were the key genes, and overlap genes were analyzed to perform Gene Ontology and KEGG pathway analysis and retrieve interacting genes; (2) tumorigenesis and recurrence were contributed by different genes, we would find key genes from clusters SC and CR individually, and SC and CR genes were individually analyzed to perform Gene Ontology and KEGG pathway analysis and retrieve interacting genes. For method 1, Venny 2.1.0 (<http://bioinfogp.cnb.csic.es/tools/venny/index.html>) was used to identify overlapping differentially expressed genes between SC and CR. The upregulated and downregulated genes were measured, respectively.

2.4. Gene Ontology and KEGG Pathway Analysis {#sec2.4}
--------------------------------------------

The Database for Annotation, Visualization, and Integrated Discovery (DAVID, <https://david.ncifcrf.gov/>) was used to perform Gene Ontology (GO) functional and KEGG pathway enrichment analyses. *p* \< 0.05 was considered as statistically significant.

2.5. Retrieving Interacting Genes {#sec2.5}
---------------------------------

Search Tool for the Retrieval of Interacting Genes (STRING) is an online tool ([https://string-db.org](https://string-db.org/)) designed to integrate information by consolidating known and predicted protein-protein association data. Molecular Complex Detection (MCODE) in Cytoscape software (Cytoscape_v3.6.1) was applied to screen hub genes. All identified differentially expressed genes described above were analyzed. The top 20 hub genes with connection degree \>10 were selected.

2.6. Survival Analysis {#sec2.6}
----------------------

The protein expression and raw survival data were downloaded from OncoLnc (<http://www.oncolnc.org/>). Overall survival and disease-free survival were analyzed by Gene Expression Profiling Interactive Analysis (GEPIA, online website: <http://gepia.cancer-pku.cn/detail.php?gene>).

2.7. Gene Expression Data {#sec2.7}
-------------------------

Gene expression data were obtained from ONCOMINE website ([https://www.oncomine.org/](https://www.oncomine.org/resource/login.html)). Cancer type was restricted by bladder cancer, and the expressions of CCNB1, ESPL1, CENPM, BLM, ASPM, JUN, and CDK6 were obtained.

2.8. Statistical Analysis {#sec2.8}
-------------------------

Clinical information was analyzed by SPSS 18.0 (IBM Corporation, Armonk, NY). A Cox regression model was conducted to perform univariate and multivariate analyses. The gene expressions were analyzed by GraphPad Prism 7.0. *p* \< 0.05 is considered to reveal a statistically significant difference.

3. Results {#sec3}
==========

Analysis was performed using data for 58 normal tissues surrounding cancer, 165 primary bladder cancer samples, and 23 recurrent cancer samples. We identified 4211 differentially expressed genes (DEGs) by analysis of surrounding tissue vs. cancer tissue (SC analysis) and 410 DEGs by analysis of cancer tissue vs. recurrent tissue cluster (CR analysis). There were 1657 and 258 upregulated DEGs in cluster SC and cluster CR, respectively, and 2514 and 152 individually downregulated DEGs in cluster SC and cluster CR. A comparison of these sets of genes revealed 148 overlap genes, including 91 upregulated and 57 downregulated DEGs ([Figure 1](#fig1){ref-type="fig"}). We next analyzed these genes by performing two kinds of functional analysis.

3.1. Gene Ontology and KEGG Pathway Analysis {#sec3.1}
--------------------------------------------

In the first analysis, the 91 upregulated and 57 downregulated genes that were differentially expressed in both the comparison of cancer and surrounding tissues and the comparison of cancer and recurrent cancer tissues were analyzed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID; <https://david.ncifcrf.gov/>). Gene Ontology (GO) functional and KEGG pathway enrichment analyses were performed. GO function analysis revealed enrichment of these DEGs in functions related to the cytoplasm and nucleoplasm. There is an enrichment of genes involved with protein binding and protein kinase binding, regulating cell division, DNA replication, and cyclin-dependent protein serine/threonine kinase activity. KEGG pathway analysis indicated that the identified DEGs are mainly enriched in the PI3K-Akt signaling pathway, microRNAs related to cancer, and the cell cycle. The 15 most enriched classes based on GO function analysis and the eight most enriched KEGG pathways are listed in [Table 1](#tab1){ref-type="table"}.

In the second analysis, we focused on the DEGs identified by the comparison of cancer and surrounding tissues or those identified by the comparison of cancer and recurrent cancer samples. Analysis of DEGs from the surrounding tissue vs. cancer tissue comparison should reflect key genes participating in tumorigenesis or bladder cancer development. GO function analysis of these genes found high enrichment of functions related to extracellular exosomes, extracellular space, and extracellular matrix. Protein binding, heparin binding, and integrin binding are the main functions of these genes, which participate in cell adhesion, extracellular matrix organization, and aging. KEGG pathway analysis indicated enrichment of these genes in HTLV-I infection, *Staphylococcus aureus* infection, and focal adhesion ([Table 2](#tab2){ref-type="table"}). We next analyzed the DEGs identified by the comparison of cancer and recurrent cancer samples, which should include genes related to bladder cancer recurrence. GO function analysis revealed enrichment of these genes in functions related to the cytoplasm, cytosol, and nucleoplasm, and analysis of molecular function showed enrichment in protein binding. The most relevant enriched biological processes are angiogenesis and the G1/S transition of the mitotic cell cycle, and KEGG pathway analysis indicated enrichment of these genes in cancer pathways, the PI3K-Akt signaling pathway, and cell cycle ([Table 2](#tab2){ref-type="table"}).

3.2. Hub Gene Analysis {#sec3.2}
----------------------

We used STRING for investigating and integrating interaction between proteins. Data were exported for further analysis by Cytoscape. We defined the top 20 genes with the highest degree of connectivity as the hub genes. For method 1, 20 hub genes are shown in [Figure 2(a)](#fig2){ref-type="fig"}. Also, hub genes in clusters SC and CR are shown in Figures [2(b)](#fig2){ref-type="fig"} and [2(c)](#fig2){ref-type="fig"}.

3.3. Clinical Analysis {#sec3.3}
----------------------

Kaplan--Meier analysis was performed for the identified hub genes using the DAVID website. We defined the 20 genes with the highest degree of connectivity as hub genes and determined hub genes for the SC comparison and for the CR comparison. For the 20 hub genes identified in the SC analysis, JUN and CDK6 were associated with the overall survival of bladder cancer patients (Figures [3(j)](#fig3){ref-type="fig"} and [3(o)](#fig3){ref-type="fig"}). High JUN expression increased the risk of death by 40% relative to low JUN expression (*p*=0.041), and high CDK6 expression increased the risk of death by 50% compared to low CDK6 expression (*p*=0.013). Overall survival analysis of other hub genes did not exhibit statistical significance for high and low expressions (Figures [3(a)](#fig3){ref-type="fig"}--[3(i)](#fig3){ref-type="fig"}, [3(k)](#fig3){ref-type="fig"}--[3(n)](#fig3){ref-type="fig"}, and [3(p)](#fig3){ref-type="fig"}--[3(t)](#fig3){ref-type="fig"}).

We also determined 20 hub genes for the CR analysis. None of these hub genes were associated with overall survival (Supplement [](#supplementary-material-1){ref-type="supplementary-material"}). We next analyzed the hub genes and their association with disease-free survival (DFS) instead of overall survival. In this analysis, we found an association of CDK6 with DFS of bladder cancer patients (Supplement [](#supplementary-material-1){ref-type="supplementary-material"}).

We then downloaded the raw data from OncoLnc for further analysis. Cox regression revealed that CCNB1, ESPL1, CENPM, BLM, and ASPM are related to overall survival (Supplement [](#supplementary-material-1){ref-type="supplementary-material"}). Of these, CCNB1, ESPL1, CENPM, and BLM were identified as hub genes from cluster CR, and ASPM was identified as a hub gene from cluster SC (Supplement [](#supplementary-material-1){ref-type="supplementary-material"}).

3.4. Gene Expression in BC {#sec3.4}
--------------------------

The expressions of CCNB1, ESPL1, CENPM, BLM, ASPM, and two other genes (JUN and CDK6) associated with bladder cancer patient overall survival are shown in [Figure 4](#fig4){ref-type="fig"} and Supplement [](#supplementary-material-1){ref-type="supplementary-material"}. The expression levels of CCNB1, ESPL1, CENPM, BLM, and ASPM were 4.795-, 5.028-, 8.691-, 2.083-, and 3.725-fold higher in BC than in normal tissues (*p* = 3.86*E*−13, 5.92*E*−20, 5.91*E*−26, 5.19*E*−14, and 2.56*E*−13). The expressions of JUN and CDK6 were not significantly different between BC and normal tissues (*p* = 0.639 and 0.466).

4. Discussion {#sec4}
=============

In this analysis, we defined differentially expressed genes for the SC comparison of surrounding tissue vs. cancer tissue and for the CR comparison of cancer tissue vs. recurrent tissue and considered the identified DEGs contributing to BC development and contributing to BC recurrence, respectively. Genes found in both SC and CR analyses affect both BC development and recurrence, and key genes identified in either SC analysis or CR analysis but not in both analyses are genes that affect either BC development or recurrence, respectively. GO function analysis discovered DEGs are mainly enriched in cytoplasm and nucleoplasm for both clusters, and KEGG pathway analysis indicated high enrichment of DEGs in the PI3K-Akt signaling pathway. We found that CCNB1, ESPL1, CENPM, BLM, and ASPM may be associated with BC development, and CCNB1, ESPL1, CENPM, and BLM may be associated with BC recurrence. It was interesting that our analysis revealed four genes, CCNB1, ESPL1, CENPM, and BLM, which are associated with both BC development and recurrence. Although JUN and CDK6 were not associated with BC development or recurrence, they may be prognostic factors for overall survival ([Figure 3(j)](#fig3){ref-type="fig"}, [3(o)](#fig3){ref-type="fig"}). The *p* value was unadjusted for tumor recurrence, and without a correction for multiple tests, the results are meaningful but not conclusive for recurrent tumors.

Among the identified genes, we found CCNB1 was 4.8-fold more highly expressed in BC compared to the level in normal tissues (*p* = 3.86*E*−13). CCNB1 is an important cell cycle protein and is a key regulator of the G2/M checkpoint. High levels of CCNB1 usually lead to cell immortalization, resulting in aneuploidy, which contributes to chromosomal instability and is related to the aggressive nature of certain cancers \[[@B14]\]. The involvement of CCNB1 with BC was demonstrated previously \[[@B15]--[@B19]\]. Three bioinformatics analyses indicated that CCNB1 was a key gene in BC, consistent with our findings \[[@B17]--[@B19]\]; however, other hub genes reported previously such as KIF4A, TPX2, BUB1B, CDK1, ISG15, KIF15, RAD54L, and TRIP13 were not identified in our analysis. CCNB1 has been positively correlated with cell proliferation, invasion, and migration \[[@B20]\]. Gene expression profiling in 102 patients with non-muscle-invasive BC identified an association of CCNB1 with disease recurrence \[[@B16]\], and other analyses showed a positive correlation of CCNB1 with pathological stage and metastasis \[[@B20]\]. Cytological experiments may be required to confirm the function of CCNB1 in BC cells.

Our analysis discovered ESPL1 was expressed at a level 5.0-fold higher in BC than the level in normal tissues (*p* = 5.92*E*−20). ESPL1, also known as extra spindle poles-like 1 protein or separin, plays a central role in chromosome segregation by cleaving the cohesin complex at the onset of anaphase, and altered ESPL1 activity is correlated with aneuploidy and cancer \[[@B21]\]. Genomic analysis of transitional cell carcinoma (TCC) by both whole-genome and whole-exome sequencing of 99 individuals with TCC found frequent alterations in ESPL1 \[[@B22]\]. ESPL1 expression was negatively correlated with gastric adenocarcinoma pathologic stage progression, and the high expression of ESPL1 was significantly correlated with favorable outcomes \[[@B23]\]. In contrast, ESPL1 functions as an oncogene rather than as an antioncogene in breast cancer \[[@B24]\]. Further work is required to resolve the conflicting roles of ESPL1 in cancer and determine its function in BC.

CENPM was also identified as a key gene associated with BC. CENPM showed an 8.7-fold higher expression in BC compared to the levels in normal tissues (*p* = 5.91*E*−26). A study comparing the effects of garlic extracts and cisplatin for the treatment of BC identified 515 common anticancer genes, including CENPM. BC patients with low expression of CENPM showed significantly better progression-free survival than those with high expression of CENPM \[[@B25]\]. CENPM encodes centromere protein M, which is a component of the CENPA-NAC (nucleosome-associated) complex. The complex plays a central role in the assembly of kinetochore proteins, mitotic progression, and chromosome segregation \[[@B26]\]. Thus, we speculated that CENPM may be an important gene in BC development and recurrence.

BLM participates in DNA replication and repair and plays an important role in the maintenance of genome stability \[[@B27], [@B28]\]. Mutations altering BLM function are associated with highly elevated cancer susceptibility \[[@B29]\]. Its roles in BC are unknown, and our research suggests BLM function may be related to BC development and recurrence. The expression of BLM was 2.1-fold higher in BC than the level in normal tissues (*p* = 5.19*E*−14), but further research will be required to uncover the underlying mechanisms.

ASPM is the only gene that we found involved that was associated with BC development but not recurrence (Supplement [](#supplementary-material-1){ref-type="supplementary-material"}). ASPM exhibited a 3.7-fold higher expression level in BC than the level in normal tissues (*p* = 2.56*E*−13). Abnormal spindle-like microcephaly-associated protein is encoded by ASPM and is involved in mitotic spindle regulation and the coordination of mitotic processes \[[@B30]\]. Recently, another study reported significant overexpression of ASPM in bladder cancer that was associated with invasive pathological characteristics \[[@B31]\]. These results support our findings linking ASPM function to BC.

There are some limitations of this analysis that are worth noting. First, this research was based on data from a single gene array, so the inclusion of other expression data would strengthen the conclusions. Second, altered expression levels of these genes in BC have not been verified by biological methods, so additional experiments to knock down or overexpress these genes should be conducted. Finally, a major drawback of this study is insufficient evidence to suggest changes at the protein level, since the analysis was based only on mRNA expression data and protein interactions were predicted by STRING.

In conclusion, our study suggested CCNB1, ESPL1, CENPM, BLM, and ASPM may be associated with BC development, and CCNB1, ESPL1, CENPM, and BLM may be associated with BC recurrence. The functions of most of these candidate genes have not been the focus of previous studies of BC, and their functions in this cancer should be verified by in vivo and in vitro experiments.
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###### 

Supplement figure 1: overall survival analysis for 20 hub genes from cluster SC (surrounding tissue vs. cancer tissue) (A: CDK1; B. CCNB1; C: CDC20; D: CCNA2; E: AURKB; F: EZH2; G: KIF2C; H: AURKA; I: TOP2A; J: BUB1B; K: BUB1; L: CCNB2; M: CDCA8; N: KIF20A; O: TPX2; P: CDC45; Q: FOXM1; R: KIF4A; S: ASPM; T: NDC80). None of the hub genes showed statistical significance in comparing overall survival for high and low expression. Supplement figure 2: disease-free survival analysis for 20 hub genes from cluster CR (cancer tissue vs. recurrent tissue) (A: CCNB1; B: JUN; C: CCNB2; D: ESPL1; E: RHOA; F: CDC45; G: MKI67; H: CDK4; I: AR; J: CDT1; K: FANCI; L: PRC1; M: MCM10; N: CDC25A; O: ASF1B; P: CDK6; Q: BLM; R: CENPM; S: CDKN1A; T: CCR7). Only (P) CDK6 (HR = 1.4, *p* = 0.015) showed statistical significance that higher expression patients indicated poor disease-free survival. Supplement figure 3: the expressions of (A) JUN and (B) CDK6 were not significantly different between BC and normal tissues (*p* = 0.639 and 0.466). Supplement Table 1: Cox regression for hub genes in bladder cancer and clinical info.

###### 

Click here for additional data file.

![4211 differentially expressed genes (DEGs) were found by comparing 58 normal tissues surrounding cancer and 165 primary bladder cancer samples, and 410 DEGs were found by comparing 165 primary bladder cancer and 23 recurrent samples. There were 1657 and 258 upregulated DEGs and 2514 and 152 individually downregulated DEGs for each group. 91 and 57 overlap genes were found in up- and downregulation genes.](BMRI2019-3917982.001){#fig1}

![(a) According to method 1, 20 hub genes were discovered from overlapping differentially expressed genes between SC (surrounding tissue vs. cancer tissue) and CR (cancer tissue vs. recurrent tissue). (b) 20 hub genes were discovered from SC. (c) 20 hub genes were discovered from CR.](BMRI2019-3917982.002){#fig2}

![Overall survival analysis for 20 hub genes from method 1: (a) CCNB1, (b) CCNB2, (c) ESPL1, (d) CDC45, (e) FANCI, (f) MCM10, (g) CDT1, (h) PRC1, (i) MKI67, (j) JUN, (k) ASP1B, (l) CENPM, (m) SGOL1, (n) CDC25A, (o) CDK6, (p) CDCA3, (q) TACC3, (r) TROAP, (s) CDK4, and (t) BLM. For the 20 hub genes, only (j) JUN (HR = 1.4, *p*=0.041) and (o) CDK6 (HR = 1.5, *p*=0.013) showed statistical significance that higher expression patients indicated poor overall survival.](BMRI2019-3917982.003){#fig3}

![(a) CCNB1, (b) ESPL1, (c) CENPM, (d) BLM, and (e) ASPM were 4.795-, 5.028-, 8.691-, 2.083-, and 3.725-fold higher in BC than in normal tissues (*p* = 3.86*E*−13, 5.92*E*−20, 5.91*E*−26, 5.19*E*−14, and 2.56*E*−13, respectively).](BMRI2019-3917982.004){#fig4}

###### 

Gene ontology and KEGG pathway analysis of differentially expressed genes according to method 1.

                     Category                                                               Term                     Count              \%                  *p* value
  ------------------ ---------------------------------------------------------------------- ------------------------ ------------------ ------------------- ------------------
  *GO analysis*      GOTERM_CC_DIRECT                                                       GO:0005654∼nucleoplasm   42                 28.1879194630872    1.22*E* − 05
  GOTERM_MF_DIRECT   GO:0005515∼protein binding                                             92                       61.744966442953    8.65*E* − 05        
  GOTERM_BP_DIRECT   GO:0051301∼cell division                                               12                       8.05369127516778   1.08*E* − 04        
  GOTERM_BP_DIRECT   GO:0006260∼DNA replication                                             8                        5.36912751677852   2.35*E* − 04        
  GOTERM_CC_DIRECT   GO:0005737∼cytoplasm                                                   60                       40.2684563758389   2.68*E* − 04        
  GOTERM_MF_DIRECT   GO:0019901∼protein kinase binding                                      11                       7.38255033557047   7.94*E* − 04        
  GOTERM_BP_DIRECT   GO:0000082∼G1/S transition of mitotic cell cycle                       6                        4.02684563758389   0.001302766851924   
  GOTERM_CC_DIRECT   GO:0000922∼spindle pole                                                6                        4.02684563758389   0.001440410268581   
  GOTERM_MF_DIRECT   GO:0004693∼cyclin-dependent protein serine/threonine kinase activity   4                        2.68456375838926   0.002393195271174   
  GOTERM_BP_DIRECT   GO:0001706∼endoderm formation                                          3                        2.01342281879194   0.003901253353245   
  GOTERM_CC_DIRECT   GO:0005813∼centrosome                                                  10                       6.71140939597315   0.005184882974603   
  GOTERM_CC_DIRECT   GO:0005739∼mitochondrion                                               20                       13.4228187919463   0.005522684005422   
  GOTERM_BP_DIRECT   GO:0051591∼response to cAMP                                            4                        2.68456375838926   0.005751402857203   
  GOTERM_BP_DIRECT   GO:0098609∼cell-cell adhesion                                          8                        5.36912751677852   0.005854477268833   
  GOTERM_CC_DIRECT   GO:0005829∼cytosol                                                     38                       25.5033557046979   0.007692882731082   
                                                                                                                                                            
  *KEGG pathway*     KEGG_PATHWAY                                                           hsa04110: cell cycle     7                  4.6979865771812     0.00123536590764
  KEGG_PATHWAY       hsa05222: small cell lung cancer                                       5                        3.35570469798657   0.009218413749072   
  KEGG_PATHWAY       hsa04151: PI3K-Akt signaling pathway                                   9                        6.04026845637583   0.018153887794995   
  KEGG_PATHWAY       hsa05206: microRNAs in cancer                                          8                        5.36912751677852   0.020570720541055   
  KEGG_PATHWAY       hsa04115: p53 signaling pathway                                        4                        2.68456375838926   0.02717134771579    
  KEGG_PATHWAY       hsa04920: adipocytokine signaling pathway                              4                        2.68456375838926   0.030418432882382   
  KEGG_PATHWAY       hsa04152: AMPK signaling pathway                                       5                        3.35570469798657   0.031444562545736   
  KEGG_PATHWAY       hsa04068: FoxO signaling pathway                                       5                        3.35570469798657   0.04111192229316    

BP: biological process; CC: cellular component; GO: gene ontology; MF: molecular function.

###### 

Gene ontology and KEGG pathway analysis of differentially expressed genes in bladder cancer development and recurrence.

                     Bladder cancer development                                   Bladder cancer recurrence                                                                                                                                                                                                                  
  ------------------ ------------------------------------------------------------ ---------------------------------- ------------------- ------------------ ------------------ ---------------------------------------------------------------------- ------------------------------ ------------------- ------------------- -------------------
  *GO analysis*      GOTERM_CC_DIRECT                                             GO:0070062∼extracellular exosome   331                 25.5007704160246   6.61*E* − 26       GOTERM_MF_DIRECT                                                       GO:0005515∼protein binding     233                 57.2481572481572    5.48*E* − 07
  GOTERM_CC_DIRECT   GO:0031012∼+A1                                               69                                 5.31587057010785    2.26*E* − 19       GOTERM_CC_DIRECT   GO:0005737∼cytoplasm                                                   152                            37.3464373464373    1.25*E* − 06        
  GOTERM_CC_DIRECT   GO:0005615∼extracellular space                               164                                12.6348228043143    1.98*E* − 13       GOTERM_CC_DIRECT   GO:0005654∼nucleoplasm                                                 86                             21.1302211302211    1.16*E* − 04        
  GOTERM_BP_DIRECT   GO:0030198∼extracellular matrix organization                 46                                 3.54391371340523    9.99*E* − 13       GOTERM_CC_DIRECT   GO:0016020∼membrane                                                    70                             17.1990171990172    2.74*E* − 04        
  GOTERM_CC_DIRECT   GO:0005578∼proteinaceous extracellular matrix                54                                 4.16024653312788    1.67*E* − 12       GOTERM_CC_DIRECT   GO:0005829∼cytosol                                                     96                             23.5872235872235    4.19*E* − 04        
  GOTERM_CC_DIRECT   GO:0005925∼focal adhesion                                    67                                 5.16178736517719    6.60*E* − 12       GOTERM_CC_DIRECT   GO:0070062∼extracellular exosome                                       83                             20.3931203931203    6.83*E* − 04        
  GOTERM_CC_DIRECT   GO:0009986∼cell surface                                      82                                 6.31741140215716    1.84*E* − 11       GOTERM_MF_DIRECT   GO:0004693∼cyclin-dependent protein serine/threonine kinase activity   6                              1.47420147420147    7.00*E* − 04        
  GOTERM_BP_DIRECT   GO:0007155∼cell adhesion                                     73                                 5.62403697996918    9.83*E* − 11       GOTERM_MF_DIRECT   GO:0030332∼cyclin binding                                              5                              1.22850122850122    7.36*E* − 04        
  GOTERM_CC_DIRECT   GO:0005576∼extracellular region                              175                                13.4822804314329    3.89*E* − 10       GOTERM_BP_DIRECT   GO:0048146∼positive regulation of fibroblast proliferation             7                              1.71990171990172    8.99*E* − 04        
  GOTERM_MF_DIRECT   GO:0005515∼protein binding                                   711                                54.7765793528505    8.26*E* − 10       GOTERM_BP_DIRECT   GO:0000082∼G1/S transition of mitotic cell cycle                       9                              2.21130221130221    0.001364705455254   
  GOTERM_MF_DIRECT   GO:0008201∼heparin binding                                   35                                 2.69645608628659    3.49*E* − 09       GOTERM_BP_DIRECT   GO:0048839∼inner ear development                                       6                              1.47420147420147    0.00158628474829    
  GOTERM_MF_DIRECT   GO:0005178∼integrin binding                                  27                                 2.08012326656394    8.57*E* − 09       GOTERM_BP_DIRECT   GO:0031581∼hemidesmosome assembly                                      4                              0.982800982800982   0.001745599823436   
  GOTERM_BP_DIRECT   GO:0048146∼positive regulation of fibroblast proliferation   19                                 1.46 *E* + 00       1.38*E* − 08       GOTERM_BP_DIRECT   GO:0051591∼response to cAMP                                            6                              1.47420147420147    0.002664403703622   
  GOTERM_BP_DIRECT   GO:0007568∼aging                                             33                                 2.54237288135593    1.37*E* − 07       GOTERM_BP_DIRECT   GO:0001525∼angiogenesis                                                13                             3.19410319410319    0.002731528888927   
  GOTERM_BP_DIRECT   GO:0060333∼interferon-gamma-mediated signaling pathway       20                                 1.54083204930662    2.89*E* − 07       GOTERM_CC_DIRECT   GO:0005615∼extracellular space                                         44                             10.8108108108108    0.003130126302432   
                                                                                                                                                                                                                                                                                                                             
  *KEGG pathway*     KEGG_PATHWAY                                                 hsa05166: HTLV-I infection         49                  3.77503852080123   1.54*E* − 08       KEGG_PATHWAY                                                           hsa05200: pathways in cancer   22                  5.4054054054054     0.001345594815917
  KEGG_PATHWAY       hsa05150: *Staphylococcus aureus* infection                  20                                 1.54083204930662    1.67*E* − 08       KEGG_PATHWAY       hsa04151: PI3K-Akt signaling pathway                                   19                             4.66830466830466    0.003848355864399   
  KEGG_PATHWAY       hsa04510: focal adhesion                                     40                                 3.08166409861325    3.47*E* − 07       KEGG_PATHWAY       hsa04923: regulation of lipolysis in adipocytes                        6                              1.47420147420147    0.015090205294328   
  KEGG_PATHWAY       hsa05323: rheumatoid arthritis                               23                                 1.77195685670261    1.19*E* − 06       KEGG_PATHWAY       hsa04110: cell cycle                                                   9                              2.21130221130221    0.015736544810328   
  KEGG_PATHWAY       hsa05416: viral myocarditis                                  18                                 1.38674884437596    1.41*E* − 06       KEGG_PATHWAY       hsa05222: small cell lung cancer                                       7                              1.71990171990172    0.023482661953239   
  KEGG_PATHWAY       hsa04514: cell adhesion molecules (CAMs)                     30                                 2.31124807395993    2.37*E* − 06       KEGG_PATHWAY       hsa00010: glycolysis/gluconeogenesis                                   6                              1.47420147420147    0.03037227765735    
  KEGG_PATHWAY       hsa05310: asthma                                             12                                 0.924499229583975   1.17*E* − 05       KEGG_PATHWAY       hsa03320: PPAR signaling pathway                                       6                              1.47420147420147    0.03037227765735    
  KEGG_PATHWAY       hsa04110: cell cycle                                         26                                 2.00308166409861    1.49*E* − 05       KEGG_PATHWAY       hsa04610: complement and coagulation cascades                          6                              1.47420147420147    0.033914937801339   
  KEGG_PATHWAY       hsa04610: complement and coagulation cascades                18                                 1.38674884437596    2.41*E* − 05       KEGG_PATHWAY       hsa05205: proteoglycans in cancer                                      11                             2.7027027027027     0.036633631217231   
  KEGG_PATHWAY       hsa04612: antigen processing and presentation                19                                 1.46379044684129    2.49*E* − 05       KEGG_PATHWAY       hsa04921: oxytocin signaling pathway                                   9                              2.21130221130221    0.042657563729801   

BP: biological process; CC: cellular component; GO: gene ontology; MF: molecular function.
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